The ability of innate immune cells to sense and respond to impending danger varies by anatomical location. The liver is considered tolerogenic but is still capable of mounting a successful immune response to clear various infections. To understand whether hepatic immune cells tune their response to different infectious challenges, we probed mononuclear cells purified from human healthy and diseased livers with distinct pathogen-associated molecules. We discovered that only the TLR8 agonist ssRNA40 selectively activated liver-resident innate immune cells to produce substantial quantities of IFN-γ. We identified CD161Bright mucosal-associated invariant T (MAIT) and CD56Bright NK cells as the responding liver-resident innate immune cells. Their activation was not directly induced by the TLR8 agonist but was dependent on IL-12 and IL-18 production by ssRNA40-activated intrahepatic monocytes. Importantly, the ssRNA40-induced cytokine-dependent activation of MAIT cells mirrored responses induced by bacteria, i.e., generating a selective production of high levels of IFN-γ, without the concomitant production of TNF-α or IL-17A. The intrahepatic IFN-γ production could be detected not only in healthy livers, but also in HBV- or HCV-infected livers. In conclusion, the human liver harbors a network of immune cells able to modulate their immunological responses to different pathogen-associated molecules. Their ability to generate a strong production of IFN-γ upon stimulation with TLR8 agonist opens new therapeutic opportunities for the treatment of diverse liver pathologies.
References
[1]
Protzer U, Maini MK, Knolle PA (2012) Living in the liver: hepatic infections. Nat Rev Immunol 12: 201–213. doi: 10.1038/nri3169
[2]
Raz E (2007) Organ-specific regulation of innate immunity. Nat Immunol 8: 3–4. doi: 10.1038/ni0107-3
[3]
Crispe IN (2009) The liver as a lymphoid organ. Annu Rev Immunol 27: 147–163. doi: 10.1146/annurev.immunol.021908.132629
[4]
Chisari FV, Nakamura M, Milich DR, Han K, Molden D, et al. (1985) Production of two distinct and independent hepatic immunoregulatory molecules by the perfused rat liver. Hepatology 5: 735–743. doi: 10.1002/hep.1840050506
[5]
Lee WY, Moriarty TJ, Wong CH, Zhou H, Strieter RM, et al. (2010) An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 11: 295–302. doi: 10.1038/ni.1855
[6]
Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, et al. (2008) TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 205: 233–244. doi: 10.1084/jem.20072195
[7]
Treiner E, Lantz O (2006) CD1d- and MR1-restricted invariant T cells: of mice and men. Curr Opin Immunol 18: 519–526. doi: 10.1016/j.coi.2006.07.001
[8]
Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, et al. (2013) IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 190: 3142–3152. doi: 10.4049/jimmunol.1203218
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, et al. (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526–1529. doi: 10.1126/science.1093620
[11]
Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, et al. (2012) MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491: 717–723. doi: 10.1038/nature11605
[12]
Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, et al. (2012) Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun 80: 3256–3267. doi: 10.1128/iai.00279-12
[13]
Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, et al. (2014) CD161(++) CD8(+) T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol 44: 195–203. doi: 10.1002/eji.201343509
[14]
Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, et al. (2010) Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33: 375–386. doi: 10.1016/j.immuni.2010.08.012
[15]
Cavanaugh VJ, Guidotti LG, Chisari FV (1997) Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 71: 3236–3243.
[16]
Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV (2002) Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 76: 10702–10707. doi: 10.1128/jvi.76.21.10702-10707.2002
[17]
Lau DT, Negash A, Chen J, Crochet N, Sinha M, et al. (2013) Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 144: 402–e412, 402-413, e412. doi: 10.1053/j.gastro.2012.10.044
[18]
Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, et al. (2013) GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology 144: 1508–e1510, 1508-1517, e1510. doi: 10.1053/j.gastro.2013.02.003
[19]
Liaskou E, Zimmermann HW, Li KK, Oo YH, Suresh S, et al. (2013) Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology 57: 385–398. doi: 10.1002/hep.26016
[20]
Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, et al. (2010) Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6: e1001227. doi: 10.1371/journal.ppat.1001227
[21]
Cervantes JL, Dunham-Ems SM, La Vake CJ, Petzke MM, Sahay B, et al. (2011) Phagosomal signaling by Borrelia burgdorferi in human monocytes involves Toll-like receptor (TLR) 2 and TLR8 cooperativity and TLR8-mediated induction of IFN-beta. Proc Natl Acad Sci U S A 108: 3683–3688. doi: 10.1073/pnas.1013776108
[22]
Gantier MP, Irving AT, Kaparakis-Liaskos M, Xu D, Evans VA, et al. (2010) Genetic modulation of TLR8 response following bacterial phagocytosis. Hum Mutat 31: 1069–1079. doi: 10.1002/humu.21321
[23]
Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165–175. doi: 10.1016/j.immuni.2005.06.008
[24]
Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, et al. (2011) Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 474: 385–389. doi: 10.1038/nature10072
[25]
Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, et al. (2010) Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 11: 701–708. doi: 10.1038/ni.1890
[26]
Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, et al. (2005) Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42: 724–731. doi: 10.1002/hep.20839
[27]
Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, et al. (2006) Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A 103: 1828–1833. doi: 10.1073/pnas.0510801103
[28]
Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529–1531. doi: 10.1126/science.1093616
[29]
Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, et al. (1999) Viral clearance without destruction of infected cells during acute HBV infection. Science 284: 825–829. doi: 10.1126/science.284.5415.825
[30]
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, et al. (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25–36. doi: 10.1016/s1074-7613(00)80295-2
[31]
Fosdick A, Zheng J, Pflanz S, Frey CR, Hesselgesser J, et al. (2014) Pharmacokinetic and Pharmacodynamic Properties of GS-9620, a Novel Toll-Like Receptor 7 Agonist, Demonstrate Interferon-Stimulated Gene Induction without Detectable Serum Interferon at Low Oral Doses. J Pharmacol Exp Ther 348: 96–105. doi: 10.1124/jpet.113.207878
[32]
Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, et al. (2013) The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 9: e1003208. doi: 10.1371/journal.ppat.1003208
[33]
Lan P, Zhang C, Han Q, Zhang J, Tian Z (2013) Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology 58: 73–85. doi: 10.1002/hep.26339
[34]
Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, et al. (2010) A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 52: 330–339. doi: 10.1016/j.jhep.2009.12.015
[35]
Schenkel JM, Fraser KA, Vezys V, Masopust D (2013) Sensing and alarm function of resident memory CD8(+) T cells. Nat Immunol 14: 509–513. doi: 10.1038/ni.2568
[36]
Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, et al. (2001) Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 194: 1755–1766. doi: 10.1084/jem.194.12.1755
[37]
Tumas DB, Zheng X, Rhodes G, Duatschek P, Hesselgesser J, et al. (2011) Preclinical characterization of GS-9620, a potent and selective oral TLR7 agonist. J Hepatol 56: S180. doi: 10.1016/s0168-8278(11)61131-8
